Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases - Wikidata - thesis-toulmin - TriplyDB

Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases

Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases

http://www.wikidata.org/entity/Q28744267

about

The interplay between inflammation and metabolism in rheumatoid arthritis NCOA5 haploinsufficiency results in glucose intolerance and subsequent hepatocellular carcinoma Association between the interleukin-6 promoter polymorphism -174G/C and serum lipoprotein(a) concentrations in humans Adipocytokines in obesity and metabolic disease.Correlation Among Hypoglycemia, Glycemic Variability, and C-Peptide Preservation After Alefacept Therapy in Patients with Type 1 Diabetes Mellitus: Analysis of Data from the Immune Tolerance Network T1DAL Trial.Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a).Inflammation, lipid metabolism and cardiovascular risk in rheumatoid arthritis: A qualitative relationship?Cardiovascular involvement in autoimmune diseases.Pro-inflammatory wnt5a and anti-inflammatory sFRP5 are differentially regulated by nutritional factors in obese human subjects.Mechanisms of premature atherosclerosis in rheumatoid arthritis and lupus Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease.Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment Insulin resistance, selfish brain, and selfish immune system: an evolutionarily positively selected program used in chronic inflammatory diseases.B-1a lymphocytes attenuate insulin resistance B Lymphocyte Stimulator (BLyS) is expressed in human adipocytes in vivo and is related to obesity but not to insulin resistance.Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis.IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans.Pulse Wave Velocity, Intima Media Thickness, and Flow-mediated Dilatation in Patients with Normotensive Normoglycemic Inflammatory Bowel Disease.Obesity Is a Positive Modulator of IL-6R and IL-6 Expression in the Subcutaneous Adipose Tissue: Significance for Metabolic Inflammation Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions.Cardiovascular disease and rheumatoid arthritis: an update.Atherogenic index and high-density lipoprotein cholesterol as cardiovascular risk determinants in rheumatoid arthritis: the impact of therapy with biologicals Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis.A Systematic Literature Review of the Association of Lipoprotein(a) and Autoimmune Diseases and Atherosclerosis.Lipoprotein(a) metabolism: potential sites for therapeutic targets.Inflammation during obesity is not all bad: evidence from animal and human studies.Lipoprotein(a): a promising marker for residual cardiovascular risk assessment.The potential role of ‘non-rheumatic’ therapies in rheumatic disease.Cardiovascular safety of biologic therapies for the treatment of RA.Cardiovascular metabolic syndrome: mediators involved in the pathophysiology from obesity to coronary heart disease.Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases.Anti-cytokine therapies in T1D: Concepts and strategies.Adipose tissue inflammation in glucose metabolism.Role of innate immune response in non-alcoholic Fatty liver disease: metabolic complications and therapeutic tools.Lipoprotein(a) as a therapeutic target in cardiovascular disease.Specific therapy to regulate inflammation in rheumatoid arthritis: molecular aspects.IL-6 biology: implications for clinical targeting in rheumatic disease.Targeting lipoprotein (a): an evolving therapeutic landscape.Cardiac involvement in primary systemic vasculitis and potential drug therapies to reduce cardiovascular risk.Metabolic Instruction of Immunity.

P2860

Q26785751-96C43028-7243-401E-AEBF-745DD8E96D86 Q28586911-A12C1E5B-6181-47CF-8A50-B1F9B260F54E Q28740387-4C6C36D2-FF51-48EB-94AD-C9A450B5034D Q30357655-E2DAAE04-2780-462C-AC84-93F39914AFB9 Q31099230-15DD673B-540B-4B94-9A29-D3A22CCD4736 Q33561072-ABA6FE60-55D0-4AE0-AC8C-6340C7A59ADF Q33891946-41905ADE-2319-49B3-B9E0-EEB8AB4A2916 Q34081242-6A33622F-0C9A-4F7D-A6EE-4CD2CE4EB2EA Q34182705-B120BEFF-0EF0-4FED-8444-7859FE21EACA Q34343906-5E8317A7-C564-438D-A997-AD265325C2F3 Q34444895-B92ECE09-2093-4343-BFDA-5124FDA748E6 Q34563216-1577954A-7837-4BFC-BDC5-4B5999DAF9B8 Q34597334-2EA0EBDA-BCC0-4805-8508-8EFE5943F1F1 Q35004327-149588D8-CEF9-4339-A8FF-1D4B5CDE75FF Q35146857-95395C9A-0A7C-4A4D-B162-3980C88DFC3A Q35257568-8E24F69E-933C-460F-90CA-D276C2056C64 Q35536380-75482650-C47A-4C6D-9F86-94166A30F294 Q35670684-D092DAEE-B0D0-4DD2-9FEF-6349FFCAAFCB Q35705451-C3D1D435-162B-4E5F-849F-559A4E13548B Q35724900-F9BCB790-5911-4822-B15C-797D4D10560E Q36218375-C048CC83-B09F-4F72-9B23-88D8039FAC5A Q36238859-00FFA1C7-7FC4-449F-AD22-C063E66A7556 Q36464352-EF8E165E-BBF2-409D-8EDD-4F5ECB97D238 Q36469043-AB738F3C-DAA3-4469-9A0E-5E5A71D44868 Q36539756-8479EAF2-512C-4E29-8933-F2AC53C84900 Q37174503-427FC6C2-8E40-4512-8B9A-D1E809A604D0 Q37285933-FD54EDAA-469B-4EBF-B2E8-7FEE27B7023E Q37690154-A3F777D6-ACF6-455B-98CE-7EBFDCFC9080 Q37956137-4C3C579C-28C0-499F-8F8C-638CE852EE0D Q37980497-BFF7FC8E-1F7C-424B-B632-030E2502529A Q38058508-0D2D9A12-F019-4431-8840-36182396F071 Q38091182-D0B653B5-C275-4342-AD08-FA54FD654D68 Q38139293-91B1D6E4-B8A0-4A00-9E1B-4991079EE445 Q38209324-5C2BBC19-9F5F-4801-AB14-689A1C994F0A Q38213476-11B0D993-80AD-4191-8B67-74B1A3FEA237 Q38217595-E8B7C48B-736C-4519-94F9-117F4C0AE24C Q38241232-E2871C85-2244-4DAD-87CB-73BEC89D7AB0 Q38367355-F4E448EC-CFEA-40E5-96AE-026D2C471A7D Q38737288-9FF9EF97-0B16-41A5-A4DA-103685393E15 Q39286043-70698E75-A3F6-4D6E-8D39-8A9F4D589360

P2860

Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases

http://www.wikidata.org/entity/Q28744267

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Effects of inhibition of inter ...... jects with rheumatoid diseases

@ast

Effects of inhibition of inter ...... jects with rheumatoid diseases

@en

Effects of inhibition of inter ...... jects with rheumatoid diseases

@nl

type

label

Effects of inhibition of inter ...... jects with rheumatoid diseases

@ast

Effects of inhibition of inter ...... jects with rheumatoid diseases

@en

Effects of inhibition of inter ...... jects with rheumatoid diseases

@nl

prefLabel

Effects of inhibition of inter ...... jects with rheumatoid diseases

@ast

Effects of inhibition of inter ...... jects with rheumatoid diseases

@en

Effects of inhibition of inter ...... jects with rheumatoid diseases

@nl

P1433

Q28744267-318E037C-2165-45BE-B7A9-1185E2A0ACE4

P1476

Q28744267-8B1D1014-099D-47D4-8D89-B22FAE6D74C2

P2093

Q28744267-08108933-163A-40E0-9A89-1BB1E8955E6F

Q28744267-6666A7F8-C24B-4635-8726-C63A18CC4F0E

Q28744267-85FFEFC4-B90D-4ABF-BB62-CADF1B9E1D6D

Q28744267-873D4E8C-6835-4178-A095-1989D9B72721

Q28744267-DD1AD380-8C80-44E1-91F1-A1ADC59DF4F1

Q28744267-DDDDFB8F-F269-4BF9-AD8B-447C4E96C5BA

Q28744267-F76EFD13-030D-4CA1-BA3B-77CE86B471A8

P2860

Q28744267-05CC4CD2-B3D8-40BA-893E-E12FCD381124

Q28744267-0CEE90E2-1FED-439F-BF4C-681B80A21867

Q28744267-198009D1-C2E5-46B4-85D7-8B7EDBBFF8E0

Q28744267-1A856395-1BE4-48BA-B692-1E58DAB6EE2D

Q28744267-1AB37EA0-405F-41E6-874A-E56F56B57929

Q28744267-24D68ED4-5364-4903-897D-E2D5387149A6

Q28744267-24EF8159-C4FC-4831-AD98-2FDB99225D6E

Q28744267-3681951A-7F99-4336-A373-2C6B91043DA0

Q28744267-39C3AD5F-6538-4601-97F2-4FE4E41283C0

Q28744267-3B9FB6E9-8670-4AC8-9E9E-734E1FBDD3DC

P304

Q28744267-E0C10545-D85C-4C44-806B-296550AFAD46

P31

Q28744267-15E40ADC-F1B1-46DD-9BDA-0634C0EE1E6C

P356

Q28744267-9D8EF69B-A55D-46DF-BEF9-69A58A8B0BAD

P407

Q28744267-AEAB7176-8959-4E86-A9D4-5D7595D88963

P433

Q28744267-A028DC56-6A24-4A02-97AB-11853ABD2A59

P478

Q28744267-DE09E9AF-45D8-480F-8C7A-B0597264EADA

P50

Q28744267-12A87919-58D8-402B-994A-1A8ABCD36E3B

P577

Q28744267-1B016478-3B2A-4937-8782-296446AC7D3E

P5875

Q28744267-09BD3D34-25E7-4D16-820E-A1F4FA522AE3

P698

Q28744267-DCCA6E4B-5C2B-4489-ACED-C616849FA600

P921

Q28744267-1C3553F2-7EF9-409F-B53A-5D1DA17F09CB

Q28744267-6FB39DE4-62D4-421A-B976-00F4B5012F72

Q28744267-A85A3A6C-7AD5-4783-B333-B1C49EB347A0

Q28744267-E0A426B6-13F2-42C1-B2E6-EC190DEE1AE9

Q28744267-ecf70da6-275b-469d-b3b0-8fe1cf96a035

P932

Q28744267-F6D1A9C1-5A5E-4C1B-9FC8-798EF2FAD1B8

P356

JOURNAL.PONE.0014328

P1433

P1476

Effects of inhibition of inter ...... jects with rheumatoid diseases

@en

P2093

Andrea Rubbert-Roth

http://www.w3.org/2001/XMLSchema#string

Frank Oberhauser

http://www.w3.org/2001/XMLSchema#string

Jasemine Saech

http://www.w3.org/2001/XMLSchema#string

Matthias Laudes

http://www.w3.org/2001/XMLSchema#string

Moritz Hahn

http://www.w3.org/2001/XMLSchema#string

Olaf Schultz

http://www.w3.org/2001/XMLSchema#string

Wilhelm Krone

http://www.w3.org/2001/XMLSchema#string

P2860

Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic dr

cDNA sequence of human apolipoprotein(a) is homologous to plasminogen

MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity

Interleukin-1-receptor antagonist in type 2 diabetes mellitus

Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review

IL6 gene promoter polymorphisms and type 2 diabetes: joint analysis of individual participants' data from 21 studies.

Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women.

Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance.

Interleukin-6 and diabetes: the good, the bad, or the indifferent?

P304

e14328

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0014328

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Andrea Rubbert-Roth

P577

2010-12-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49703184

http://www.w3.org/2001/XMLSchema#string

P698

21179199

http://www.w3.org/2001/XMLSchema#string

P921

human subject research

P932

3001451

http://www.w3.org/2001/XMLSchema#string